Enter title of document

SC 13G 1 taysha13g.htm Enter title of document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
Amendment #
TAYSHA GENE THERAPIES, INC.
(Name of Issuer)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
877619106
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[   ] Rule 13d-1(b)
[  ] Rule 13d-1(c)
[ x ] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 877619106
(1)		Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)
The University of Texas/Texas A&M Investment Management Company 74-2765082
(2)		Check the Appropriate Box if a Member of a Group (See Instructions)
(a)  N/A
(b)  N/A
(3)		SEC Use Only
(4)		Citizenship or Place of Organization
Texas
Numbers of Shares Beneficially Owned by Each Reporting Person With	(5)		Sole Voting Power
0
	(6)		Shared Voting Power
2,179,000
	(7)		Sole Dispositive Power
0
	(8)		Shared Dispositive Power
2,179,000
(9)		Aggregate Amount Beneficially Owned by Each Reporting Person
2,179,000
(10)		Check if the Aggregate Amount in Row (9) Excludes Certain Shares [  ]
Not applicable.
(11)		Percent of Class Represented by Amount in Row (9)
5.77%
(12)		Type of Reporting Person (See Instructions)
IA

CUSIP No. 877619106
(1)		Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)
The Board of Regents of the University of Texas System 74-6000203
(2)		Check the Appropriate Box if a Member of a Group (See Instructions)
(a)  N/A
(b)  N/A
(3)		SEC Use Only
(4)		Citizenship or Place of Organization
Texas
Numbers of Shares Beneficially Owned by Each Reporting Person With	(5)		Sole Voting Power
0
	(6)		Shared Voting Power
2,179,000
	(7)		Sole Dispositive Power
0
	(8)		Shared Dispositive Power
2,179,000
(9)		Aggregate Amount Beneficially Owned by Each Reporting Person
2,179,000
(10)		Check if the Aggregate Amount in Row (9) Excludes Certain Shares [  ]
Not applicable.
(11)		Percent of Class Represented by Amount in Row (9)
5.77%
(12)		Type of Reporting Person (See Instructions)
OO


Item 1.
(a)	Name of Issuer
Taysha Gene Therapies, Inc.
(b)	Address of Issuers Principal Executive Offices
2280 Inwood Road
Dallas, TX 75235
Item 2.
(a)	Name of Person Filing
(i)	The University of Texas/Texas A&M Investment Management Company
(ii)	The Board of Regents of the University of Texas System
The shares of Taysha Gene Therapies, Inc. common stock, $0.00001 par value per share, reported on this Schedule 13G (the Shares) were issued to The Board of Regents of the University of Texas System (the Regents) pursuant to a Research, Collaboration & License Agreement between the Issuer and the Regents, on behalf of The University of Texas Southwestern (the License Agreement) dated prior to the Issuers Initial Public Offering. Pursuant to an Investment Management Services Agreement with the Regents, The University of Texas/Texas A&M Investment Management Company (UTIMCO), an institutional investment advisor, holds the Shares on behalf of the Regents and is authorized to exercise investment discretion and voting power with respect to such Shares on behalf of the Regents.
This Schedule 13G is filed on behalf of each of these persons. Included in this Schedule 13G as Exhibit 1 is the agreement between UTIMCO and the Regents to file this Schedule 13G on behalf of each of them.
(b)	Address of Principal Business Office or, if none, Residence
(i)	210 West 7th St., Suite 1700, Austin, TX 78701
(ii)	210 West 7th St., Suite 1700, Austin, TX 78701
(c)	Citizenship
(i)	Texas
(ii)	Texas
(d)	Title of Class of Securities
Taysha Gene Therapies, Inc. common stock $0.00001 par value per share
(e)	CUSIP Number
877619106
Item 3.
Not Applicable.
Item 4.
The shares were issued to the Regents as consideration for the licensing of certain technology to the Issuer pursuant to the License Agreement. Pursuant to an Investment Management Services Agreement with the Regents, UTIMCO holds the shares on behalf of the Regents and is authorized to exercise investment discretion and voting power with respect to such shares on behalf of the Regents. Accordingly, the Regents and UTIMCO share beneficial ownership of the shares as set forth below:
(a)	Amount beneficially owned:

2,179,000

(b)	Percent of class:

5.77%

(c)	Number of shares as to which the person has:

(i)	Sole power to vote or to direct the vote
0
(ii)	Shared power to vote or to direct the vote
2,179,000
(iii)	Sole power to dispose or to direct the disposition of
0
(iv)	Shared power to dispose or to direct the disposition of
2,179,000
Item 5.	Ownership of Five Percent or Less of a Class
Not applicable.
Item 6.	 Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7.	 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable.
Item 8.	Identification and Classification of Members of the Group.
Not applicable.
Item 9.	Notice of Dissolution of Group.
Not applicable.
Item 10.	Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
The University of Texas/Texas A&M Investment Management Company
Date:  February 2, 2021	By:
		Name: Joan Moeller
		            Chief Operating Officer

The Board of Regents of the University of Texas System
By: The University of Texas/Texas A&M Investment Management Company, as investment advisor to The Board of Regents of the University of Texas System
Date:  February 2, 2021  	By:
		Name: Joan Moeller
							      Chief Operating Officer


Exhibit 1
Joint Filing Agreement
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, the entities named below agree to the joint filing on behalf of each of them of this Schedule 13G with respect to the Securities of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13G.
In evidence thereof, the undersigned hereby execute this Agreement as of February 2, 2021.

The University of Texas/Texas A&M Investment Management Company
Date:  February 2, 2021	By:
		Name: Joan Moeller
		            Chief Operating Officer

The Board of Regents of the University of Texas System
By: The University of Texas/Texas A&M Investment Management Company, as investment advisor to The Board of Regents of the University of Texas System
Date:  February 2, 2021 	By:
		Name: Joan Moeller
	   	            Chief Operating Officer
SEC Form SC 13G filed
